nodes	percent_of_prediction	percent_of_DWPC	metapath
Methotrexate—ALB—acquired immunodeficiency syndrome	0.148	1	CbGaD
Methotrexate—ABCC1—Amprenavir—acquired immunodeficiency syndrome	0.0245	0.042	CbGbCtD
Methotrexate—SLC22A6—Stavudine—acquired immunodeficiency syndrome	0.0242	0.0415	CbGbCtD
Methotrexate—SLC22A11—Zidovudine—acquired immunodeficiency syndrome	0.0238	0.0408	CbGbCtD
Methotrexate—SLC22A7—Zidovudine—acquired immunodeficiency syndrome	0.0227	0.0388	CbGbCtD
Methotrexate—ABCC3—Lamivudine—acquired immunodeficiency syndrome	0.0225	0.0384	CbGbCtD
Methotrexate—ABCC4—Zidovudine—acquired immunodeficiency syndrome	0.0222	0.0379	CbGbCtD
Methotrexate—ABCC1—Indinavir—acquired immunodeficiency syndrome	0.0212	0.0362	CbGbCtD
Methotrexate—SLCO1A2—Indinavir—acquired immunodeficiency syndrome	0.0189	0.0323	CbGbCtD
Methotrexate—ABCC1—Saquinavir—acquired immunodeficiency syndrome	0.0186	0.0318	CbGbCtD
Methotrexate—ABCC1—Ritonavir—acquired immunodeficiency syndrome	0.0186	0.0318	CbGbCtD
Methotrexate—SLC22A6—Didanosine—acquired immunodeficiency syndrome	0.0184	0.0314	CbGbCtD
Methotrexate—SLCO1A2—Nelfinavir—acquired immunodeficiency syndrome	0.0183	0.0314	CbGbCtD
Methotrexate—SLCO1B1—Indinavir—acquired immunodeficiency syndrome	0.0178	0.0305	CbGbCtD
Methotrexate—SLCO1B1—Nelfinavir—acquired immunodeficiency syndrome	0.0173	0.0296	CbGbCtD
Methotrexate—ABCC4—Lamivudine—acquired immunodeficiency syndrome	0.0172	0.0293	CbGbCtD
Methotrexate—SLCO1A2—Saquinavir—acquired immunodeficiency syndrome	0.0166	0.0284	CbGbCtD
Methotrexate—SLCO1A2—Ritonavir—acquired immunodeficiency syndrome	0.0166	0.0284	CbGbCtD
Methotrexate—ABCC2—Indinavir—acquired immunodeficiency syndrome	0.0157	0.0268	CbGbCtD
Methotrexate—SLCO1B1—Saquinavir—acquired immunodeficiency syndrome	0.0157	0.0268	CbGbCtD
Methotrexate—SLCO1B1—Ritonavir—acquired immunodeficiency syndrome	0.0157	0.0268	CbGbCtD
Methotrexate—SLC22A8—Zidovudine—acquired immunodeficiency syndrome	0.0139	0.0237	CbGbCtD
Methotrexate—ABCC1—Lamivudine—acquired immunodeficiency syndrome	0.0138	0.0236	CbGbCtD
Methotrexate—ABCC2—Saquinavir—acquired immunodeficiency syndrome	0.0138	0.0235	CbGbCtD
Methotrexate—ABCC2—Ritonavir—acquired immunodeficiency syndrome	0.0138	0.0235	CbGbCtD
Methotrexate—ABCG2—Nelfinavir—acquired immunodeficiency syndrome	0.0138	0.0235	CbGbCtD
Methotrexate—ABCG2—Saquinavir—acquired immunodeficiency syndrome	0.0124	0.0213	CbGbCtD
Methotrexate—ABCG2—Ritonavir—acquired immunodeficiency syndrome	0.0124	0.0213	CbGbCtD
Methotrexate—ABCG2—Zidovudine—acquired immunodeficiency syndrome	0.0119	0.0204	CbGbCtD
Methotrexate—ABCC2—Lamivudine—acquired immunodeficiency syndrome	0.0102	0.0175	CbGbCtD
Methotrexate—SLC22A6—Zidovudine—acquired immunodeficiency syndrome	0.00965	0.0165	CbGbCtD
Methotrexate—ABCG2—Lamivudine—acquired immunodeficiency syndrome	0.00922	0.0158	CbGbCtD
Methotrexate—ALB—Saquinavir—acquired immunodeficiency syndrome	0.00857	0.0147	CbGbCtD
Methotrexate—ALB—Zidovudine—acquired immunodeficiency syndrome	0.00822	0.0141	CbGbCtD
Methotrexate—SLC22A6—Lamivudine—acquired immunodeficiency syndrome	0.00747	0.0128	CbGbCtD
Methotrexate—ABCB1—Lopinavir—acquired immunodeficiency syndrome	0.00654	0.0112	CbGbCtD
Methotrexate—ABCB1—Amprenavir—acquired immunodeficiency syndrome	0.00592	0.0101	CbGbCtD
Methotrexate—ABCB1—Indinavir—acquired immunodeficiency syndrome	0.00511	0.00874	CbGbCtD
Methotrexate—ABCB1—Nelfinavir—acquired immunodeficiency syndrome	0.00496	0.00848	CbGbCtD
Methotrexate—ABCB1—Saquinavir—acquired immunodeficiency syndrome	0.00448	0.00767	CbGbCtD
Methotrexate—ABCB1—Ritonavir—acquired immunodeficiency syndrome	0.00448	0.00767	CbGbCtD
Methotrexate—ABCB1—Zidovudine—acquired immunodeficiency syndrome	0.0043	0.00736	CbGbCtD
Methotrexate—ABCB1—Lamivudine—acquired immunodeficiency syndrome	0.00333	0.00569	CbGbCtD
Methotrexate—ATIC—blood plasma—acquired immunodeficiency syndrome	0.00137	0.0188	CbGeAlD
Methotrexate—FOLR1—Folate Metabolism—IL4—acquired immunodeficiency syndrome	0.00124	0.0537	CbGpPWpGaD
Methotrexate—MTHFR—blood plasma—acquired immunodeficiency syndrome	0.00102	0.014	CbGeAlD
Methotrexate—FOLR1—lymphoid tissue—acquired immunodeficiency syndrome	0.000943	0.013	CbGeAlD
Methotrexate—FOLR1—blood—acquired immunodeficiency syndrome	0.000887	0.0122	CbGeAlD
Methotrexate—PGD—blood plasma—acquired immunodeficiency syndrome	0.000883	0.0121	CbGeAlD
Methotrexate—SLCO3A1—Transport of organic anions—ALB—acquired immunodeficiency syndrome	0.000859	0.0373	CbGpPWpGaD
Methotrexate—SLC19A1—lymphoid tissue—acquired immunodeficiency syndrome	0.000826	0.0114	CbGeAlD
Methotrexate—FOLR1—Folate Metabolism—ALB—acquired immunodeficiency syndrome	0.00082	0.0356	CbGpPWpGaD
Methotrexate—SLCO4C1—Transport of organic anions—ALB—acquired immunodeficiency syndrome	0.00082	0.0356	CbGpPWpGaD
Methotrexate—SLC19A1—digestive system—acquired immunodeficiency syndrome	0.000816	0.0112	CbGeAlD
Methotrexate—SLCO1B1—blood plasma—acquired immunodeficiency syndrome	0.000802	0.011	CbGeAlD
Methotrexate—SLC19A1—blood—acquired immunodeficiency syndrome	0.000778	0.0107	CbGeAlD
Methotrexate—FOLR1—lung—acquired immunodeficiency syndrome	0.000778	0.0107	CbGeAlD
Methotrexate—FPGS—retina—acquired immunodeficiency syndrome	0.000775	0.0107	CbGeAlD
Methotrexate—GGH—skin of body—acquired immunodeficiency syndrome	0.000773	0.0106	CbGeAlD
Methotrexate—ABCC3—blood plasma—acquired immunodeficiency syndrome	0.000761	0.0105	CbGeAlD
Methotrexate—ATIC—retina—acquired immunodeficiency syndrome	0.000749	0.0103	CbGeAlD
Methotrexate—FOLR1—Folate Metabolism—IFNG—acquired immunodeficiency syndrome	0.000748	0.0324	CbGpPWpGaD
Methotrexate—FOLR1—central nervous system—acquired immunodeficiency syndrome	0.000693	0.00953	CbGeAlD
Methotrexate—SLCO1C1—Transport of organic anions—ALB—acquired immunodeficiency syndrome	0.000687	0.0298	CbGpPWpGaD
Methotrexate—SLC19A1—lung—acquired immunodeficiency syndrome	0.000682	0.00938	CbGeAlD
Methotrexate—FPGS—skin of body—acquired immunodeficiency syndrome	0.00068	0.00935	CbGeAlD
Methotrexate—FOLR1—Folate Metabolism—IL2—acquired immunodeficiency syndrome	0.000665	0.0288	CbGpPWpGaD
Methotrexate—ATIC—skin of body—acquired immunodeficiency syndrome	0.000658	0.00905	CbGeAlD
Methotrexate—SLC46A1—lymphoid tissue—acquired immunodeficiency syndrome	0.000637	0.00876	CbGeAlD
Methotrexate—SLC19A1—nervous system—acquired immunodeficiency syndrome	0.000631	0.00868	CbGeAlD
Methotrexate—SLC46A1—digestive system—acquired immunodeficiency syndrome	0.000629	0.00865	CbGeAlD
Methotrexate—ABCC4—blood plasma—acquired immunodeficiency syndrome	0.000628	0.00864	CbGeAlD
Methotrexate—GGH—digestive system—acquired immunodeficiency syndrome	0.000619	0.00851	CbGeAlD
Methotrexate—SLC19A1—central nervous system—acquired immunodeficiency syndrome	0.000608	0.00836	CbGeAlD
Methotrexate—GGH—blood—acquired immunodeficiency syndrome	0.000589	0.00811	CbGeAlD
Methotrexate—SLC46A1—spinal cord—acquired immunodeficiency syndrome	0.000577	0.00794	CbGeAlD
Methotrexate—GGH—bone marrow—acquired immunodeficiency syndrome	0.00057	0.00784	CbGeAlD
Methotrexate—GGH—spinal cord—acquired immunodeficiency syndrome	0.000568	0.00781	CbGeAlD
Methotrexate—FPGS—lymphoid tissue—acquired immunodeficiency syndrome	0.000551	0.00757	CbGeAlD
Methotrexate—FOLR1—brain—acquired immunodeficiency syndrome	0.00055	0.00757	CbGeAlD
Methotrexate—SLCO3A1—retina—acquired immunodeficiency syndrome	0.000548	0.00754	CbGeAlD
Methotrexate—GGH—vagina—acquired immunodeficiency syndrome	0.000546	0.00751	CbGeAlD
Methotrexate—FPGS—digestive system—acquired immunodeficiency syndrome	0.000544	0.00748	CbGeAlD
Methotrexate—ATIC—lymphoid tissue—acquired immunodeficiency syndrome	0.000533	0.00733	CbGeAlD
Methotrexate—ATIC—digestive system—acquired immunodeficiency syndrome	0.000526	0.00724	CbGeAlD
Methotrexate—SLCO4C1—blood—acquired immunodeficiency syndrome	0.000523	0.00719	CbGeAlD
Methotrexate—FPGS—blood—acquired immunodeficiency syndrome	0.000518	0.00713	CbGeAlD
Methotrexate—GGH—lung—acquired immunodeficiency syndrome	0.000517	0.00711	CbGeAlD
Methotrexate—SLCO4C1—bone marrow—acquired immunodeficiency syndrome	0.000506	0.00696	CbGeAlD
Methotrexate—DHFR—retina—acquired immunodeficiency syndrome	0.000503	0.00692	CbGeAlD
Methotrexate—ATIC—blood—acquired immunodeficiency syndrome	0.000501	0.00689	CbGeAlD
Methotrexate—FPGS—spinal cord—acquired immunodeficiency syndrome	0.000499	0.00687	CbGeAlD
Methotrexate—SLC19A1—Folate Metabolism—IL4—acquired immunodeficiency syndrome	0.000493	0.0214	CbGpPWpGaD
Methotrexate—SLC46A1—nervous system—acquired immunodeficiency syndrome	0.000486	0.00669	CbGeAlD
Methotrexate—SLCO4C1—vagina—acquired immunodeficiency syndrome	0.000485	0.00666	CbGeAlD
Methotrexate—FOLR1—Folate Metabolism—TNF—acquired immunodeficiency syndrome	0.000484	0.021	CbGpPWpGaD
Methotrexate—PGD—retina—acquired immunodeficiency syndrome	0.000484	0.00665	CbGeAlD
Methotrexate—ATIC—spinal cord—acquired immunodeficiency syndrome	0.000483	0.00664	CbGeAlD
Methotrexate—SLC19A1—brain—acquired immunodeficiency syndrome	0.000483	0.00664	CbGeAlD
Methotrexate—FPGS—vagina—acquired immunodeficiency syndrome	0.00048	0.00661	CbGeAlD
Methotrexate—GGH—nervous system—acquired immunodeficiency syndrome	0.000478	0.00658	CbGeAlD
Methotrexate—SLCO1B3—vagina—acquired immunodeficiency syndrome	0.000471	0.00648	CbGeAlD
Methotrexate—SLC46A1—central nervous system—acquired immunodeficiency syndrome	0.000468	0.00644	CbGeAlD
Methotrexate—SLC19A1—lymph node—acquired immunodeficiency syndrome	0.000466	0.00641	CbGeAlD
Methotrexate—GGH—central nervous system—acquired immunodeficiency syndrome	0.000461	0.00634	CbGeAlD
Methotrexate—SLCO4C1—lung—acquired immunodeficiency syndrome	0.000458	0.0063	CbGeAlD
Methotrexate—FPGS—lung—acquired immunodeficiency syndrome	0.000454	0.00625	CbGeAlD
Methotrexate—SLC16A1—retina—acquired immunodeficiency syndrome	0.000451	0.00621	CbGeAlD
Methotrexate—TYMS—skin of body—acquired immunodeficiency syndrome	0.000446	0.00613	CbGeAlD
Methotrexate—SLCO1B3—lung—acquired immunodeficiency syndrome	0.000445	0.00613	CbGeAlD
Methotrexate—ATIC—lung—acquired immunodeficiency syndrome	0.000439	0.00604	CbGeAlD
Methotrexate—SLC22A11—digestive system—acquired immunodeficiency syndrome	0.000425	0.00584	CbGeAlD
Methotrexate—PGD—skin of body—acquired immunodeficiency syndrome	0.000425	0.00584	CbGeAlD
Methotrexate—FPGS—nervous system—acquired immunodeficiency syndrome	0.000421	0.00579	CbGeAlD
Methotrexate—SLC22A7—digestive system—acquired immunodeficiency syndrome	0.000415	0.0057	CbGeAlD
Methotrexate—ATIC—nervous system—acquired immunodeficiency syndrome	0.000407	0.0056	CbGeAlD
Methotrexate—FPGS—central nervous system—acquired immunodeficiency syndrome	0.000405	0.00557	CbGeAlD
Methotrexate—SLCO1C1—spinal cord—acquired immunodeficiency syndrome	0.000401	0.00552	CbGeAlD
Methotrexate—MTHFR—lymphoid tissue—acquired immunodeficiency syndrome	0.000396	0.00544	CbGeAlD
Methotrexate—ATIC—central nervous system—acquired immunodeficiency syndrome	0.000392	0.00539	CbGeAlD
Methotrexate—MTHFR—digestive system—acquired immunodeficiency syndrome	0.000391	0.00538	CbGeAlD
Methotrexate—FOLR1—Folate Metabolism—IL6—acquired immunodeficiency syndrome	0.000391	0.0169	CbGpPWpGaD
Methotrexate—SLCO1B3—Transport of organic anions—ALB—acquired immunodeficiency syndrome	0.000389	0.0169	CbGpPWpGaD
Methotrexate—MTHFR—blood—acquired immunodeficiency syndrome	0.000372	0.00512	CbGeAlD
Methotrexate—SLC46A1—brain—acquired immunodeficiency syndrome	0.000372	0.00511	CbGeAlD
Methotrexate—SLCO3A1—blood—acquired immunodeficiency syndrome	0.000366	0.00504	CbGeAlD
Methotrexate—GGH—brain—acquired immunodeficiency syndrome	0.000366	0.00503	CbGeAlD
Methotrexate—TYMS—lymphoid tissue—acquired immunodeficiency syndrome	0.000361	0.00497	CbGeAlD
Methotrexate—SLC46A1—lymph node—acquired immunodeficiency syndrome	0.000359	0.00494	CbGeAlD
Methotrexate—DHFR—lymphoid tissue—acquired immunodeficiency syndrome	0.000358	0.00492	CbGeAlD
Methotrexate—TYMS—digestive system—acquired immunodeficiency syndrome	0.000357	0.00491	CbGeAlD
Methotrexate—GGH—lymph node—acquired immunodeficiency syndrome	0.000353	0.00486	CbGeAlD
Methotrexate—DHFR—digestive system—acquired immunodeficiency syndrome	0.000353	0.00486	CbGeAlD
Methotrexate—SLCO3A1—spinal cord—acquired immunodeficiency syndrome	0.000353	0.00486	CbGeAlD
Methotrexate—TYMS—Circadian rythm related genes—CARTPT—acquired immunodeficiency syndrome	0.000352	0.0153	CbGpPWpGaD
Methotrexate—PGD—lymphoid tissue—acquired immunodeficiency syndrome	0.000344	0.00473	CbGeAlD
Methotrexate—TYMS—blood—acquired immunodeficiency syndrome	0.00034	0.00467	CbGeAlD
Methotrexate—SLCO3A1—vagina—acquired immunodeficiency syndrome	0.00034	0.00467	CbGeAlD
Methotrexate—PGD—digestive system—acquired immunodeficiency syndrome	0.00034	0.00467	CbGeAlD
Methotrexate—SLCO1C1—nervous system—acquired immunodeficiency syndrome	0.000338	0.00465	CbGeAlD
Methotrexate—DHFR—blood—acquired immunodeficiency syndrome	0.000337	0.00463	CbGeAlD
Methotrexate—TYMS—bone marrow—acquired immunodeficiency syndrome	0.000329	0.00452	CbGeAlD
Methotrexate—MTHFR—lung—acquired immunodeficiency syndrome	0.000327	0.00449	CbGeAlD
Methotrexate—SLC19A1—Folate Metabolism—ALB—acquired immunodeficiency syndrome	0.000326	0.0142	CbGpPWpGaD
Methotrexate—SLC46A1—Folate Metabolism—IL4—acquired immunodeficiency syndrome	0.000326	0.0142	CbGpPWpGaD
Methotrexate—SLCO1C1—central nervous system—acquired immunodeficiency syndrome	0.000326	0.00448	CbGeAlD
Methotrexate—DHFR—bone marrow—acquired immunodeficiency syndrome	0.000326	0.00448	CbGeAlD
Methotrexate—DHFR—spinal cord—acquired immunodeficiency syndrome	0.000324	0.00446	CbGeAlD
Methotrexate—PGD—blood—acquired immunodeficiency syndrome	0.000324	0.00445	CbGeAlD
Methotrexate—FPGS—brain—acquired immunodeficiency syndrome	0.000322	0.00442	CbGeAlD
Methotrexate—SLCO3A1—lung—acquired immunodeficiency syndrome	0.000321	0.00442	CbGeAlD
Methotrexate—SLCO3A1—Transport of vitamins, nucleosides, and related molecules—ALB—acquired immunodeficiency syndrome	0.000319	0.0138	CbGpPWpGaD
Methotrexate—SLC16A1—digestive system—acquired immunodeficiency syndrome	0.000317	0.00436	CbGeAlD
Methotrexate—TYMS—vagina—acquired immunodeficiency syndrome	0.000315	0.00433	CbGeAlD
Methotrexate—PGD—bone marrow—acquired immunodeficiency syndrome	0.000313	0.00431	CbGeAlD
Methotrexate—DHFR—vagina—acquired immunodeficiency syndrome	0.000312	0.00429	CbGeAlD
Methotrexate—PGD—spinal cord—acquired immunodeficiency syndrome	0.000312	0.00429	CbGeAlD
Methotrexate—ATIC—brain—acquired immunodeficiency syndrome	0.000311	0.00428	CbGeAlD
Methotrexate—FPGS—lymph node—acquired immunodeficiency syndrome	0.000311	0.00427	CbGeAlD
Methotrexate—SLCO1B1—digestive system—acquired immunodeficiency syndrome	0.000308	0.00424	CbGeAlD
Methotrexate—SLCO1A2—Transport of organic anions—ALB—acquired immunodeficiency syndrome	0.000306	0.0133	CbGpPWpGaD
Methotrexate—SLCO4C1—Transport of vitamins, nucleosides, and related molecules—ALB—acquired immunodeficiency syndrome	0.000304	0.0132	CbGpPWpGaD
Methotrexate—MTHFR—nervous system—acquired immunodeficiency syndrome	0.000302	0.00416	CbGeAlD
Methotrexate—ATIC—lymph node—acquired immunodeficiency syndrome	0.0003	0.00413	CbGeAlD
Methotrexate—PGD—vagina—acquired immunodeficiency syndrome	0.0003	0.00412	CbGeAlD
Methotrexate—AOX1—digestive system—acquired immunodeficiency syndrome	0.000299	0.00411	CbGeAlD
Methotrexate—TYMS—lung—acquired immunodeficiency syndrome	0.000298	0.0041	CbGeAlD
Methotrexate—SLC19A1—Folate Metabolism—IFNG—acquired immunodeficiency syndrome	0.000298	0.0129	CbGpPWpGaD
Methotrexate—SLCO3A1—nervous system—acquired immunodeficiency syndrome	0.000298	0.00409	CbGeAlD
Methotrexate—DHFR—lung—acquired immunodeficiency syndrome	0.000295	0.00406	CbGeAlD
Methotrexate—ABCC10—lymphoid tissue—acquired immunodeficiency syndrome	0.000295	0.00405	CbGeAlD
Methotrexate—SLCO1B1—blood—acquired immunodeficiency syndrome	0.000294	0.00404	CbGeAlD
Methotrexate—ABCC3—digestive system—acquired immunodeficiency syndrome	0.000293	0.00402	CbGeAlD
Methotrexate—ABCC10—digestive system—acquired immunodeficiency syndrome	0.000291	0.00401	CbGeAlD
Methotrexate—MTHFR—central nervous system—acquired immunodeficiency syndrome	0.000291	0.004	CbGeAlD
Methotrexate—SLC16A1—spinal cord—acquired immunodeficiency syndrome	0.000291	0.004	CbGeAlD
Methotrexate—SLCO1B3—Recycling of bile acids and salts—ALB—acquired immunodeficiency syndrome	0.000288	0.0125	CbGpPWpGaD
Methotrexate—SLCO3A1—central nervous system—acquired immunodeficiency syndrome	0.000286	0.00394	CbGeAlD
Methotrexate—PGD—lung—acquired immunodeficiency syndrome	0.000284	0.0039	CbGeAlD
Methotrexate—ALB—FOXA2 and FOXA3 transcription factor networks—TAT—acquired immunodeficiency syndrome	0.000283	0.0123	CbGpPWpGaD
Methotrexate—ABCC3—blood—acquired immunodeficiency syndrome	0.000279	0.00383	CbGeAlD
Methotrexate—ABCC10—blood—acquired immunodeficiency syndrome	0.000277	0.00382	CbGeAlD
Methotrexate—TYMS—nervous system—acquired immunodeficiency syndrome	0.000276	0.0038	CbGeAlD
Methotrexate—DHFR—nervous system—acquired immunodeficiency syndrome	0.000273	0.00376	CbGeAlD
Methotrexate—ABCC10—bone marrow—acquired immunodeficiency syndrome	0.000268	0.00369	CbGeAlD
Methotrexate—ABCC10—spinal cord—acquired immunodeficiency syndrome	0.000267	0.00368	CbGeAlD
Methotrexate—TYMS—central nervous system—acquired immunodeficiency syndrome	0.000266	0.00365	CbGeAlD
Methotrexate—SLC16A1—lung—acquired immunodeficiency syndrome	0.000265	0.00364	CbGeAlD
Methotrexate—SLC19A1—Folate Metabolism—IL2—acquired immunodeficiency syndrome	0.000265	0.0115	CbGpPWpGaD
Methotrexate—AOX1—vagina—acquired immunodeficiency syndrome	0.000264	0.00363	CbGeAlD
Methotrexate—DHFR—central nervous system—acquired immunodeficiency syndrome	0.000263	0.00362	CbGeAlD
Methotrexate—PGD—nervous system—acquired immunodeficiency syndrome	0.000263	0.00361	CbGeAlD
Methotrexate—SLCO1B1—Transport of organic anions—ALB—acquired immunodeficiency syndrome	0.000261	0.0113	CbGpPWpGaD
Methotrexate—ABCC3—Recycling of bile acids and salts—ALB—acquired immunodeficiency syndrome	0.00026	0.0113	CbGpPWpGaD
Methotrexate—SLCO1C1—brain—acquired immunodeficiency syndrome	0.000259	0.00356	CbGeAlD
Methotrexate—ABCC10—vagina—acquired immunodeficiency syndrome	0.000257	0.00354	CbGeAlD
Methotrexate—SLCO1C1—Transport of vitamins, nucleosides, and related molecules—ALB—acquired immunodeficiency syndrome	0.000255	0.0111	CbGpPWpGaD
Methotrexate—PGD—central nervous system—acquired immunodeficiency syndrome	0.000253	0.00348	CbGeAlD
Methotrexate—SLCO1A2—digestive system—acquired immunodeficiency syndrome	0.000251	0.00345	CbGeAlD
Methotrexate—AOX1—lung—acquired immunodeficiency syndrome	0.00025	0.00344	CbGeAlD
Methotrexate—SLCO1C1—lymph node—acquired immunodeficiency syndrome	0.00025	0.00344	CbGeAlD
Methotrexate—MTHFR—Vitamin B12 Metabolism—CCL5—acquired immunodeficiency syndrome	0.00025	0.0108	CbGpPWpGaD
Methotrexate—SLC16A1—nervous system—acquired immunodeficiency syndrome	0.000245	0.00337	CbGeAlD
Methotrexate—SLC22A7—brain—acquired immunodeficiency syndrome	0.000245	0.00337	CbGeAlD
Methotrexate—ABCC3—lung—acquired immunodeficiency syndrome	0.000244	0.00336	CbGeAlD
Methotrexate—ABCC10—lung—acquired immunodeficiency syndrome	0.000243	0.00334	CbGeAlD
Methotrexate—ABCC4—digestive system—acquired immunodeficiency syndrome	0.000242	0.00332	CbGeAlD
Methotrexate—SLC22A6—brain—acquired immunodeficiency syndrome	0.000237	0.00325	CbGeAlD
Methotrexate—SLC16A1—central nervous system—acquired immunodeficiency syndrome	0.000236	0.00325	CbGeAlD
Methotrexate—ABCC2—digestive system—acquired immunodeficiency syndrome	0.000234	0.00322	CbGeAlD
Methotrexate—MTHFR—brain—acquired immunodeficiency syndrome	0.000231	0.00318	CbGeAlD
Methotrexate—SLCO1A2—spinal cord—acquired immunodeficiency syndrome	0.00023	0.00317	CbGeAlD
Methotrexate—ABCC4—blood—acquired immunodeficiency syndrome	0.00023	0.00317	CbGeAlD
Methotrexate—SLC22A8—blood—acquired immunodeficiency syndrome	0.000228	0.00314	CbGeAlD
Methotrexate—SLCO3A1—brain—acquired immunodeficiency syndrome	0.000227	0.00313	CbGeAlD
Methotrexate—SLCO1A2—Recycling of bile acids and salts—ALB—acquired immunodeficiency syndrome	0.000227	0.00982	CbGpPWpGaD
Methotrexate—ABCC3—nervous system—acquired immunodeficiency syndrome	0.000226	0.00311	CbGeAlD
Methotrexate—MTHFR—lymph node—acquired immunodeficiency syndrome	0.000223	0.00307	CbGeAlD
Methotrexate—ABCC2—blood—acquired immunodeficiency syndrome	0.000223	0.00306	CbGeAlD
Methotrexate—ABCC4—bone marrow—acquired immunodeficiency syndrome	0.000223	0.00306	CbGeAlD
Methotrexate—SLCO3A1—lymph node—acquired immunodeficiency syndrome	0.00022	0.00302	CbGeAlD
Methotrexate—ABCB1—blood plasma—acquired immunodeficiency syndrome	0.000219	0.00301	CbGeAlD
Methotrexate—ABCC3—central nervous system—acquired immunodeficiency syndrome	0.000218	0.003	CbGeAlD
Methotrexate—SLC46A1—Folate Metabolism—ALB—acquired immunodeficiency syndrome	0.000216	0.00938	CbGpPWpGaD
Methotrexate—TYMS—brain—acquired immunodeficiency syndrome	0.000211	0.0029	CbGeAlD
Methotrexate—SLCO1A2—lung—acquired immunodeficiency syndrome	0.00021	0.00288	CbGeAlD
Methotrexate—DHFR—brain—acquired immunodeficiency syndrome	0.000209	0.00287	CbGeAlD
Methotrexate—TYMS—lymph node—acquired immunodeficiency syndrome	0.000204	0.0028	CbGeAlD
Methotrexate—DHFR—lymph node—acquired immunodeficiency syndrome	0.000202	0.00278	CbGeAlD
Methotrexate—ABCC4—lung—acquired immunodeficiency syndrome	0.000202	0.00277	CbGeAlD
Methotrexate—PGD—brain—acquired immunodeficiency syndrome	0.000201	0.00276	CbGeAlD
Methotrexate—SLC46A1—Folate Metabolism—IFNG—acquired immunodeficiency syndrome	0.000197	0.00856	CbGpPWpGaD
Methotrexate—MTHFR—Folate Metabolism—IL4—acquired immunodeficiency syndrome	0.000197	0.00854	CbGpPWpGaD
Methotrexate—ABCC1—blood—acquired immunodeficiency syndrome	0.000196	0.0027	CbGeAlD
Methotrexate—SLCO1A2—nervous system—acquired immunodeficiency syndrome	0.000194	0.00267	CbGeAlD
Methotrexate—PGD—lymph node—acquired immunodeficiency syndrome	0.000194	0.00267	CbGeAlD
Methotrexate—SLCO1B1—Recycling of bile acids and salts—ALB—acquired immunodeficiency syndrome	0.000194	0.0084	CbGpPWpGaD
Methotrexate—SLC19A1—Folate Metabolism—TNF—acquired immunodeficiency syndrome	0.000193	0.00836	CbGpPWpGaD
Methotrexate—SLC16A1—brain—acquired immunodeficiency syndrome	0.000187	0.00258	CbGeAlD
Methotrexate—SLCO1A2—central nervous system—acquired immunodeficiency syndrome	0.000187	0.00257	CbGeAlD
Methotrexate—ABCC4—nervous system—acquired immunodeficiency syndrome	0.000187	0.00257	CbGeAlD
Methotrexate—SLC22A8—nervous system—acquired immunodeficiency syndrome	0.000185	0.00255	CbGeAlD
Methotrexate—ABCC1—vagina—acquired immunodeficiency syndrome	0.000182	0.0025	CbGeAlD
Methotrexate—SLC16A1—lymph node—acquired immunodeficiency syndrome	0.000181	0.00249	CbGeAlD
Methotrexate—ABCC4—central nervous system—acquired immunodeficiency syndrome	0.00018	0.00247	CbGeAlD
Methotrexate—SLC22A8—central nervous system—acquired immunodeficiency syndrome	0.000178	0.00245	CbGeAlD
Methotrexate—AOX1—brain—acquired immunodeficiency syndrome	0.000177	0.00243	CbGeAlD
Methotrexate—SLC46A1—Folate Metabolism—IL2—acquired immunodeficiency syndrome	0.000175	0.0076	CbGpPWpGaD
Methotrexate—DHFR—Folate Metabolism—IL4—acquired immunodeficiency syndrome	0.000175	0.00759	CbGpPWpGaD
Methotrexate—ABCC3—brain—acquired immunodeficiency syndrome	0.000173	0.00238	CbGeAlD
Methotrexate—ABCC10—brain—acquired immunodeficiency syndrome	0.000172	0.00237	CbGeAlD
Methotrexate—ABCC1—lung—acquired immunodeficiency syndrome	0.000172	0.00237	CbGeAlD
Methotrexate—AOX1—lymph node—acquired immunodeficiency syndrome	0.000171	0.00235	CbGeAlD
Methotrexate—ABCC3—lymph node—acquired immunodeficiency syndrome	0.000167	0.0023	CbGeAlD
Methotrexate—ABCC10—lymph node—acquired immunodeficiency syndrome	0.000166	0.00229	CbGeAlD
Methotrexate—ABCG2—blood—acquired immunodeficiency syndrome	0.000162	0.00223	CbGeAlD
Methotrexate—MTHFR—Vitamin B12 Metabolism—ALB—acquired immunodeficiency syndrome	0.00016	0.00695	CbGpPWpGaD
Methotrexate—ABCG2—bone marrow—acquired immunodeficiency syndrome	0.000157	0.00216	CbGeAlD
Methotrexate—ABCG2—spinal cord—acquired immunodeficiency syndrome	0.000156	0.00215	CbGeAlD
Methotrexate—SLC19A1—Folate Metabolism—IL6—acquired immunodeficiency syndrome	0.000156	0.00675	CbGpPWpGaD
Methotrexate—SLCO1B3—Bile acid and bile salt metabolism—ALB—acquired immunodeficiency syndrome	0.000151	0.00654	CbGpPWpGaD
Methotrexate—ABCG2—vagina—acquired immunodeficiency syndrome	0.000151	0.00207	CbGeAlD
Methotrexate—SLC19A1—Metabolism—TAT—acquired immunodeficiency syndrome	0.000149	0.00645	CbGpPWpGaD
Methotrexate—SLCO1A2—brain—acquired immunodeficiency syndrome	0.000148	0.00204	CbGeAlD
Methotrexate—ALB—brain—acquired immunodeficiency syndrome	0.000148	0.00203	CbGeAlD
Methotrexate—MTHFR—Vitamin B12 Metabolism—IFNG—acquired immunodeficiency syndrome	0.000146	0.00635	CbGpPWpGaD
Methotrexate—SLCO1B3—Transport of vitamins, nucleosides, and related molecules—ALB—acquired immunodeficiency syndrome	0.000144	0.00626	CbGpPWpGaD
Methotrexate—ABCC4—brain—acquired immunodeficiency syndrome	0.000143	0.00196	CbGeAlD
Methotrexate—ALB—lymph node—acquired immunodeficiency syndrome	0.000143	0.00196	CbGeAlD
Methotrexate—ABCG2—lung—acquired immunodeficiency syndrome	0.000142	0.00196	CbGeAlD
Methotrexate—SLC19A1—Disease—APOBEC3G—acquired immunodeficiency syndrome	0.000142	0.00616	CbGpPWpGaD
Methotrexate—SLC22A8—brain—acquired immunodeficiency syndrome	0.000142	0.00195	CbGeAlD
Methotrexate—ABCC4—lymph node—acquired immunodeficiency syndrome	0.000138	0.0019	CbGeAlD
Methotrexate—ABCC3—Bile acid and bile salt metabolism—ALB—acquired immunodeficiency syndrome	0.000136	0.0059	CbGpPWpGaD
Methotrexate—ABCC2—lymph node—acquired immunodeficiency syndrome	0.000134	0.00184	CbGeAlD
Methotrexate—MTHFR—Folate Metabolism—ALB—acquired immunodeficiency syndrome	0.00013	0.00566	CbGpPWpGaD
Methotrexate—SLC46A1—Folate Metabolism—TNF—acquired immunodeficiency syndrome	0.000128	0.00554	CbGpPWpGaD
Methotrexate—FPGS—Metabolism—TAT—acquired immunodeficiency syndrome	0.000126	0.00549	CbGpPWpGaD
Methotrexate—SLC19A1—Metabolism—AGPS—acquired immunodeficiency syndrome	0.000126	0.00549	CbGpPWpGaD
Methotrexate—ATIC—Metabolism—TAT—acquired immunodeficiency syndrome	0.000126	0.00549	CbGpPWpGaD
Methotrexate—ABCC1—brain—acquired immunodeficiency syndrome	0.000122	0.00167	CbGeAlD
Methotrexate—SLC19A1—Disease—CCNT1—acquired immunodeficiency syndrome	0.000121	0.00524	CbGpPWpGaD
Methotrexate—FPGS—Disease—APOBEC3G—acquired immunodeficiency syndrome	0.000121	0.00524	CbGpPWpGaD
Methotrexate—ABCB1—retina—acquired immunodeficiency syndrome	0.00012	0.00165	CbGeAlD
Methotrexate—MTHFR—Folate Metabolism—IFNG—acquired immunodeficiency syndrome	0.000119	0.00516	CbGpPWpGaD
Methotrexate—SLCO1A2—Bile acid and bile salt metabolism—ALB—acquired immunodeficiency syndrome	0.000118	0.00513	CbGpPWpGaD
Methotrexate—ABCG2—HIF-1-alpha transcription factor network—CXCR4—acquired immunodeficiency syndrome	0.000118	0.00513	CbGpPWpGaD
Methotrexate—ABCG2—HIF-1-alpha transcription factor network—CXCL12—acquired immunodeficiency syndrome	0.000118	0.00513	CbGpPWpGaD
Methotrexate—ABCC1—lymph node—acquired immunodeficiency syndrome	0.000118	0.00162	CbGeAlD
Methotrexate—DHFR—Folate Metabolism—ALB—acquired immunodeficiency syndrome	0.000116	0.00503	CbGpPWpGaD
Methotrexate—SLCO1A2—Transport of vitamins, nucleosides, and related molecules—ALB—acquired immunodeficiency syndrome	0.000113	0.00492	CbGpPWpGaD
Methotrexate—FPGS—Metabolism—AGPS—acquired immunodeficiency syndrome	0.000108	0.00466	CbGpPWpGaD
Methotrexate—ATIC—Metabolism—AGPS—acquired immunodeficiency syndrome	0.000108	0.00466	CbGpPWpGaD
Methotrexate—MTHFR—Folate Metabolism—IL2—acquired immunodeficiency syndrome	0.000106	0.00459	CbGpPWpGaD
Methotrexate—DHFR—Folate Metabolism—IFNG—acquired immunodeficiency syndrome	0.000106	0.00459	CbGpPWpGaD
Methotrexate—MTHFR—Selenium Micronutrient Network—ALB—acquired immunodeficiency syndrome	0.000104	0.00449	CbGpPWpGaD
Methotrexate—SLC46A1—Folate Metabolism—IL6—acquired immunodeficiency syndrome	0.000103	0.00447	CbGpPWpGaD
Methotrexate—FPGS—Disease—CCNT1—acquired immunodeficiency syndrome	0.000103	0.00445	CbGpPWpGaD
Methotrexate—SLCO1B1—Bile acid and bile salt metabolism—ALB—acquired immunodeficiency syndrome	0.000101	0.00439	CbGpPWpGaD
Methotrexate—ABCG2—brain—acquired immunodeficiency syndrome	0.000101	0.00139	CbGeAlD
Methotrexate—SLC46A1—Metabolism—TAT—acquired immunodeficiency syndrome	9.85e-05	0.00427	CbGpPWpGaD
Methotrexate—ABCG2—lymph node—acquired immunodeficiency syndrome	9.74e-05	0.00134	CbGeAlD
Methotrexate—SLCO1B1—Transport of vitamins, nucleosides, and related molecules—ALB—acquired immunodeficiency syndrome	9.7e-05	0.00421	CbGpPWpGaD
Methotrexate—MTHFR—Vitamin B12 Metabolism—TNF—acquired immunodeficiency syndrome	9.47e-05	0.00411	CbGpPWpGaD
Methotrexate—MTHFR—Selenium Micronutrient Network—IFNG—acquired immunodeficiency syndrome	9.46e-05	0.0041	CbGpPWpGaD
Methotrexate—SLC46A1—Disease—APOBEC3G—acquired immunodeficiency syndrome	9.41e-05	0.00408	CbGpPWpGaD
Methotrexate—DHFR—Folate Metabolism—IL2—acquired immunodeficiency syndrome	9.4e-05	0.00408	CbGpPWpGaD
Methotrexate—PGD—Metabolism—TAT—acquired immunodeficiency syndrome	9.01e-05	0.00391	CbGpPWpGaD
Methotrexate—PGD—Disease—APOBEC3G—acquired immunodeficiency syndrome	8.6e-05	0.00373	CbGpPWpGaD
Methotrexate—ABCB1—lymphoid tissue—acquired immunodeficiency syndrome	8.51e-05	0.00117	CbGeAlD
Methotrexate—ABCB1—digestive system—acquired immunodeficiency syndrome	8.41e-05	0.00116	CbGeAlD
Methotrexate—SLC46A1—Metabolism—AGPS—acquired immunodeficiency syndrome	8.38e-05	0.00363	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism of lipids and lipoproteins—AGPS—acquired immunodeficiency syndrome	8.07e-05	0.0035	CbGpPWpGaD
Methotrexate—ABCB1—blood—acquired immunodeficiency syndrome	8.01e-05	0.0011	CbGeAlD
Methotrexate—SLC46A1—Disease—CCNT1—acquired immunodeficiency syndrome	8e-05	0.00347	CbGpPWpGaD
Methotrexate—ABCB1—bone marrow—acquired immunodeficiency syndrome	7.75e-05	0.00107	CbGeAlD
Methotrexate—ABCB1—spinal cord—acquired immunodeficiency syndrome	7.72e-05	0.00106	CbGeAlD
Methotrexate—MTHFR—Folate Metabolism—TNF—acquired immunodeficiency syndrome	7.7e-05	0.00334	CbGpPWpGaD
Methotrexate—PGD—Metabolism—AGPS—acquired immunodeficiency syndrome	7.66e-05	0.00332	CbGpPWpGaD
Methotrexate—MTHFR—Vitamin B12 Metabolism—IL6—acquired immunodeficiency syndrome	7.64e-05	0.00331	CbGpPWpGaD
Methotrexate—ABCB1—vagina—acquired immunodeficiency syndrome	7.42e-05	0.00102	CbGeAlD
Methotrexate—Malaise—Saquinavir—acquired immunodeficiency syndrome	7.34e-05	0.000426	CcSEcCtD
Methotrexate—Somnolence—Indinavir—acquired immunodeficiency syndrome	7.34e-05	0.000426	CcSEcCtD
Methotrexate—Asthenia—Stavudine—acquired immunodeficiency syndrome	7.32e-05	0.000426	CcSEcCtD
Methotrexate—Convulsion—Ritonavir—acquired immunodeficiency syndrome	7.32e-05	0.000426	CcSEcCtD
Methotrexate—PGD—Disease—CCNT1—acquired immunodeficiency syndrome	7.31e-05	0.00317	CbGpPWpGaD
Methotrexate—Feeling abnormal—Zidovudine—acquired immunodeficiency syndrome	7.31e-05	0.000425	CcSEcCtD
Methotrexate—Vertigo—Saquinavir—acquired immunodeficiency syndrome	7.31e-05	0.000425	CcSEcCtD
Methotrexate—Thrombocytopenia—Delavirdine—acquired immunodeficiency syndrome	7.3e-05	0.000425	CcSEcCtD
Methotrexate—ABCC3—Metabolism of lipids and lipoproteins—AGPS—acquired immunodeficiency syndrome	7.29e-05	0.00316	CbGpPWpGaD
Methotrexate—Leukopenia—Saquinavir—acquired immunodeficiency syndrome	7.28e-05	0.000423	CcSEcCtD
Methotrexate—Dyspepsia—Indinavir—acquired immunodeficiency syndrome	7.26e-05	0.000422	CcSEcCtD
Methotrexate—Gastrointestinal pain—Zidovudine—acquired immunodeficiency syndrome	7.26e-05	0.000422	CcSEcCtD
Methotrexate—Skin disorder—Delavirdine—acquired immunodeficiency syndrome	7.25e-05	0.000421	CcSEcCtD
Methotrexate—Pruritus—Nelfinavir—acquired immunodeficiency syndrome	7.24e-05	0.000421	CcSEcCtD
Methotrexate—Diarrhoea—Nevirapine—acquired immunodeficiency syndrome	7.23e-05	0.00042	CcSEcCtD
Methotrexate—Pruritus—Stavudine—acquired immunodeficiency syndrome	7.22e-05	0.00042	CcSEcCtD
Methotrexate—Asthenia—Abacavir—acquired immunodeficiency syndrome	7.22e-05	0.000419	CcSEcCtD
Methotrexate—Hyperhidrosis—Delavirdine—acquired immunodeficiency syndrome	7.21e-05	0.000419	CcSEcCtD
Methotrexate—Ill-defined disorder—Lamivudine—acquired immunodeficiency syndrome	7.2e-05	0.000419	CcSEcCtD
Methotrexate—Arthralgia—Ritonavir—acquired immunodeficiency syndrome	7.2e-05	0.000418	CcSEcCtD
Methotrexate—Myalgia—Ritonavir—acquired immunodeficiency syndrome	7.2e-05	0.000418	CcSEcCtD
Methotrexate—Chest pain—Ritonavir—acquired immunodeficiency syndrome	7.2e-05	0.000418	CcSEcCtD
Methotrexate—Decreased appetite—Indinavir—acquired immunodeficiency syndrome	7.17e-05	0.000417	CcSEcCtD
Methotrexate—Anaemia—Lamivudine—acquired immunodeficiency syndrome	7.17e-05	0.000417	CcSEcCtD
Methotrexate—Unspecified disorder of skin and subcutaneous tissue—Ritonavir—acquired immunodeficiency syndrome	7.15e-05	0.000415	CcSEcCtD
Methotrexate—Gastrointestinal disorder—Indinavir—acquired immunodeficiency syndrome	7.12e-05	0.000414	CcSEcCtD
Methotrexate—Pruritus—Abacavir—acquired immunodeficiency syndrome	7.11e-05	0.000414	CcSEcCtD
Methotrexate—Fatigue—Indinavir—acquired immunodeficiency syndrome	7.11e-05	0.000414	CcSEcCtD
Methotrexate—Anorexia—Delavirdine—acquired immunodeficiency syndrome	7.11e-05	0.000413	CcSEcCtD
Methotrexate—Discomfort—Ritonavir—acquired immunodeficiency syndrome	7.11e-05	0.000413	CcSEcCtD
Methotrexate—Musculoskeletal discomfort—Efavirenz—acquired immunodeficiency syndrome	7.1e-05	0.000413	CcSEcCtD
Methotrexate—Cough—Saquinavir—acquired immunodeficiency syndrome	7.1e-05	0.000413	CcSEcCtD
Methotrexate—Pain—Indinavir—acquired immunodeficiency syndrome	7.06e-05	0.00041	CcSEcCtD
Methotrexate—Insomnia—Efavirenz—acquired immunodeficiency syndrome	7.05e-05	0.00041	CcSEcCtD
Methotrexate—Urticaria—Zidovudine—acquired immunodeficiency syndrome	7.05e-05	0.00041	CcSEcCtD
Methotrexate—Convulsion—Saquinavir—acquired immunodeficiency syndrome	7.05e-05	0.00041	CcSEcCtD
Methotrexate—ABCB1—lung—acquired immunodeficiency syndrome	7.02e-05	0.000966	CbGeAlD
Methotrexate—Body temperature increased—Zidovudine—acquired immunodeficiency syndrome	7.01e-05	0.000408	CcSEcCtD
Methotrexate—Abdominal pain—Zidovudine—acquired immunodeficiency syndrome	7.01e-05	0.000408	CcSEcCtD
Methotrexate—Diarrhoea—Nelfinavir—acquired immunodeficiency syndrome	7.01e-05	0.000407	CcSEcCtD
Methotrexate—Paraesthesia—Efavirenz—acquired immunodeficiency syndrome	7e-05	0.000407	CcSEcCtD
Methotrexate—Malaise—Lamivudine—acquired immunodeficiency syndrome	7e-05	0.000407	CcSEcCtD
Methotrexate—Diarrhoea—Stavudine—acquired immunodeficiency syndrome	6.98e-05	0.000406	CcSEcCtD
Methotrexate—Nausea—Didanosine—acquired immunodeficiency syndrome	6.98e-05	0.000406	CcSEcCtD
Methotrexate—Vertigo—Lamivudine—acquired immunodeficiency syndrome	6.97e-05	0.000405	CcSEcCtD
Methotrexate—Hypotension—Delavirdine—acquired immunodeficiency syndrome	6.97e-05	0.000405	CcSEcCtD
Methotrexate—Confusional state—Ritonavir—acquired immunodeficiency syndrome	6.96e-05	0.000404	CcSEcCtD
Methotrexate—Dyspnoea—Efavirenz—acquired immunodeficiency syndrome	6.95e-05	0.000404	CcSEcCtD
Methotrexate—Leukopenia—Lamivudine—acquired immunodeficiency syndrome	6.95e-05	0.000404	CcSEcCtD
Methotrexate—Somnolence—Efavirenz—acquired immunodeficiency syndrome	6.93e-05	0.000403	CcSEcCtD
Methotrexate—Myalgia—Saquinavir—acquired immunodeficiency syndrome	6.93e-05	0.000403	CcSEcCtD
Methotrexate—Arthralgia—Saquinavir—acquired immunodeficiency syndrome	6.93e-05	0.000403	CcSEcCtD
Methotrexate—Chest pain—Saquinavir—acquired immunodeficiency syndrome	6.93e-05	0.000403	CcSEcCtD
Methotrexate—Diarrhoea—Abacavir—acquired immunodeficiency syndrome	6.88e-05	0.0004	CcSEcCtD
Methotrexate—Unspecified disorder of skin and subcutaneous tissue—Saquinavir—acquired immunodeficiency syndrome	6.88e-05	0.0004	CcSEcCtD
Methotrexate—Dyspepsia—Efavirenz—acquired immunodeficiency syndrome	6.86e-05	0.000399	CcSEcCtD
Methotrexate—DHFR—Folate Metabolism—TNF—acquired immunodeficiency syndrome	6.85e-05	0.00297	CbGpPWpGaD
Methotrexate—SLCO3A1—SLC-mediated transmembrane transport—ALB—acquired immunodeficiency syndrome	6.84e-05	0.00297	CbGpPWpGaD
Methotrexate—Discomfort—Saquinavir—acquired immunodeficiency syndrome	6.84e-05	0.000398	CcSEcCtD
Methotrexate—ALB—Vitamin B12 Metabolism—CCL5—acquired immunodeficiency syndrome	6.82e-05	0.00296	CbGpPWpGaD
Methotrexate—Feeling abnormal—Indinavir—acquired immunodeficiency syndrome	6.8e-05	0.000395	CcSEcCtD
Methotrexate—Musculoskeletal discomfort—Delavirdine—acquired immunodeficiency syndrome	6.8e-05	0.000395	CcSEcCtD
Methotrexate—Decreased appetite—Efavirenz—acquired immunodeficiency syndrome	6.78e-05	0.000394	CcSEcCtD
Methotrexate—Cough—Lamivudine—acquired immunodeficiency syndrome	6.77e-05	0.000394	CcSEcCtD
Methotrexate—Dizziness—Nelfinavir—acquired immunodeficiency syndrome	6.77e-05	0.000394	CcSEcCtD
Methotrexate—Nervous system disorder—Ritonavir—acquired immunodeficiency syndrome	6.76e-05	0.000393	CcSEcCtD
Methotrexate—Thrombocytopenia—Ritonavir—acquired immunodeficiency syndrome	6.75e-05	0.000393	CcSEcCtD
Methotrexate—Dizziness—Stavudine—acquired immunodeficiency syndrome	6.75e-05	0.000392	CcSEcCtD
Methotrexate—ABCC4—Platelet degranulation—ALB—acquired immunodeficiency syndrome	6.75e-05	0.00293	CbGpPWpGaD
Methotrexate—Gastrointestinal pain—Indinavir—acquired immunodeficiency syndrome	6.75e-05	0.000392	CcSEcCtD
Methotrexate—Insomnia—Delavirdine—acquired immunodeficiency syndrome	6.75e-05	0.000392	CcSEcCtD
Methotrexate—Gastrointestinal disorder—Efavirenz—acquired immunodeficiency syndrome	6.73e-05	0.000391	CcSEcCtD
Methotrexate—Convulsion—Lamivudine—acquired immunodeficiency syndrome	6.72e-05	0.000391	CcSEcCtD
Methotrexate—Vomiting—Nevirapine—acquired immunodeficiency syndrome	6.72e-05	0.000391	CcSEcCtD
Methotrexate—Fatigue—Efavirenz—acquired immunodeficiency syndrome	6.72e-05	0.000391	CcSEcCtD
Methotrexate—Skin disorder—Ritonavir—acquired immunodeficiency syndrome	6.7e-05	0.000389	CcSEcCtD
Methotrexate—Paraesthesia—Delavirdine—acquired immunodeficiency syndrome	6.7e-05	0.000389	CcSEcCtD
Methotrexate—Confusional state—Saquinavir—acquired immunodeficiency syndrome	6.69e-05	0.000389	CcSEcCtD
Methotrexate—Hyperhidrosis—Ritonavir—acquired immunodeficiency syndrome	6.67e-05	0.000388	CcSEcCtD
Methotrexate—Pain—Efavirenz—acquired immunodeficiency syndrome	6.67e-05	0.000388	CcSEcCtD
Methotrexate—Rash—Nevirapine—acquired immunodeficiency syndrome	6.67e-05	0.000387	CcSEcCtD
Methotrexate—Dermatitis—Nevirapine—acquired immunodeficiency syndrome	6.66e-05	0.000387	CcSEcCtD
Methotrexate—Dyspnoea—Delavirdine—acquired immunodeficiency syndrome	6.65e-05	0.000387	CcSEcCtD
Methotrexate—Dizziness—Abacavir—acquired immunodeficiency syndrome	6.65e-05	0.000387	CcSEcCtD
Methotrexate—Somnolence—Delavirdine—acquired immunodeficiency syndrome	6.63e-05	0.000385	CcSEcCtD
Methotrexate—Headache—Nevirapine—acquired immunodeficiency syndrome	6.62e-05	0.000385	CcSEcCtD
Methotrexate—Myalgia—Lamivudine—acquired immunodeficiency syndrome	6.61e-05	0.000384	CcSEcCtD
Methotrexate—Chest pain—Lamivudine—acquired immunodeficiency syndrome	6.61e-05	0.000384	CcSEcCtD
Methotrexate—Arthralgia—Lamivudine—acquired immunodeficiency syndrome	6.61e-05	0.000384	CcSEcCtD
Methotrexate—Infection—Saquinavir—acquired immunodeficiency syndrome	6.6e-05	0.000383	CcSEcCtD
Methotrexate—Anorexia—Ritonavir—acquired immunodeficiency syndrome	6.58e-05	0.000382	CcSEcCtD
Methotrexate—Dyspepsia—Delavirdine—acquired immunodeficiency syndrome	6.57e-05	0.000382	CcSEcCtD
Methotrexate—Unspecified disorder of skin and subcutaneous tissue—Lamivudine—acquired immunodeficiency syndrome	6.56e-05	0.000381	CcSEcCtD
Methotrexate—Urticaria—Indinavir—acquired immunodeficiency syndrome	6.56e-05	0.000381	CcSEcCtD
Methotrexate—SLCO4C1—SLC-mediated transmembrane transport—ALB—acquired immunodeficiency syndrome	6.53e-05	0.00283	CbGpPWpGaD
Methotrexate—Discomfort—Lamivudine—acquired immunodeficiency syndrome	6.53e-05	0.000379	CcSEcCtD
Methotrexate—Abdominal pain—Indinavir—acquired immunodeficiency syndrome	6.52e-05	0.000379	CcSEcCtD
Methotrexate—Body temperature increased—Indinavir—acquired immunodeficiency syndrome	6.52e-05	0.000379	CcSEcCtD
Methotrexate—Nervous system disorder—Saquinavir—acquired immunodeficiency syndrome	6.51e-05	0.000378	CcSEcCtD
Methotrexate—Vomiting—Nelfinavir—acquired immunodeficiency syndrome	6.51e-05	0.000378	CcSEcCtD
Methotrexate—ABCB1—nervous system—acquired immunodeficiency syndrome	6.5e-05	0.000894	CbGeAlD
Methotrexate—Thrombocytopenia—Saquinavir—acquired immunodeficiency syndrome	6.5e-05	0.000378	CcSEcCtD
Methotrexate—Vomiting—Stavudine—acquired immunodeficiency syndrome	6.49e-05	0.000377	CcSEcCtD
Methotrexate—Decreased appetite—Delavirdine—acquired immunodeficiency syndrome	6.48e-05	0.000377	CcSEcCtD
Methotrexate—Rash—Nelfinavir—acquired immunodeficiency syndrome	6.46e-05	0.000375	CcSEcCtD
Methotrexate—Dermatitis—Nelfinavir—acquired immunodeficiency syndrome	6.45e-05	0.000375	CcSEcCtD
Methotrexate—Skin disorder—Saquinavir—acquired immunodeficiency syndrome	6.45e-05	0.000375	CcSEcCtD
Methotrexate—Hypotension—Ritonavir—acquired immunodeficiency syndrome	6.45e-05	0.000375	CcSEcCtD
Methotrexate—Gastrointestinal disorder—Delavirdine—acquired immunodeficiency syndrome	6.44e-05	0.000374	CcSEcCtD
Methotrexate—Rash—Stavudine—acquired immunodeficiency syndrome	6.44e-05	0.000374	CcSEcCtD
Methotrexate—Fatigue—Delavirdine—acquired immunodeficiency syndrome	6.43e-05	0.000374	CcSEcCtD
Methotrexate—Dermatitis—Stavudine—acquired immunodeficiency syndrome	6.43e-05	0.000374	CcSEcCtD
Methotrexate—ABCC4—Response to elevated platelet cytosolic Ca2+—ALB—acquired immunodeficiency syndrome	6.43e-05	0.00279	CbGpPWpGaD
Methotrexate—Feeling abnormal—Efavirenz—acquired immunodeficiency syndrome	6.42e-05	0.000373	CcSEcCtD
Methotrexate—Hyperhidrosis—Saquinavir—acquired immunodeficiency syndrome	6.42e-05	0.000373	CcSEcCtD
Methotrexate—Headache—Nelfinavir—acquired immunodeficiency syndrome	6.41e-05	0.000373	CcSEcCtD
Methotrexate—Headache—Stavudine—acquired immunodeficiency syndrome	6.39e-05	0.000372	CcSEcCtD
Methotrexate—Vomiting—Abacavir—acquired immunodeficiency syndrome	6.39e-05	0.000372	CcSEcCtD
Methotrexate—ABCB1—HIF-1-alpha transcription factor network—CXCL12—acquired immunodeficiency syndrome	6.39e-05	0.00277	CbGpPWpGaD
Methotrexate—ABCB1—HIF-1-alpha transcription factor network—CXCR4—acquired immunodeficiency syndrome	6.39e-05	0.00277	CbGpPWpGaD
Methotrexate—Confusional state—Lamivudine—acquired immunodeficiency syndrome	6.39e-05	0.000371	CcSEcCtD
Methotrexate—Pain—Delavirdine—acquired immunodeficiency syndrome	6.38e-05	0.000371	CcSEcCtD
Methotrexate—Gastrointestinal pain—Efavirenz—acquired immunodeficiency syndrome	6.37e-05	0.000371	CcSEcCtD
Methotrexate—Asthenia—Zidovudine—acquired immunodeficiency syndrome	6.37e-05	0.00037	CcSEcCtD
Methotrexate—SLCO1A2—Metabolism of lipids and lipoproteins—AGPS—acquired immunodeficiency syndrome	6.34e-05	0.00275	CbGpPWpGaD
Methotrexate—SLC19A1—Disease—CXCR4—acquired immunodeficiency syndrome	6.34e-05	0.00275	CbGpPWpGaD
Methotrexate—Rash—Abacavir—acquired immunodeficiency syndrome	6.34e-05	0.000369	CcSEcCtD
Methotrexate—Dermatitis—Abacavir—acquired immunodeficiency syndrome	6.33e-05	0.000368	CcSEcCtD
Methotrexate—Anaphylactic shock—Lamivudine—acquired immunodeficiency syndrome	6.33e-05	0.000368	CcSEcCtD
Methotrexate—Anorexia—Saquinavir—acquired immunodeficiency syndrome	6.33e-05	0.000368	CcSEcCtD
Methotrexate—Headache—Abacavir—acquired immunodeficiency syndrome	6.3e-05	0.000366	CcSEcCtD
Methotrexate—Infection—Lamivudine—acquired immunodeficiency syndrome	6.29e-05	0.000366	CcSEcCtD
Methotrexate—Musculoskeletal discomfort—Ritonavir—acquired immunodeficiency syndrome	6.28e-05	0.000365	CcSEcCtD
Methotrexate—Nausea—Nevirapine—acquired immunodeficiency syndrome	6.28e-05	0.000365	CcSEcCtD
Methotrexate—Pruritus—Zidovudine—acquired immunodeficiency syndrome	6.28e-05	0.000365	CcSEcCtD
Methotrexate—ABCB1—central nervous system—acquired immunodeficiency syndrome	6.26e-05	0.000861	CbGeAlD
Methotrexate—Insomnia—Ritonavir—acquired immunodeficiency syndrome	6.24e-05	0.000363	CcSEcCtD
Methotrexate—MTHFR—Folate Metabolism—IL6—acquired immunodeficiency syndrome	6.22e-05	0.0027	CbGpPWpGaD
Methotrexate—Nervous system disorder—Lamivudine—acquired immunodeficiency syndrome	6.21e-05	0.000361	CcSEcCtD
Methotrexate—Hypotension—Saquinavir—acquired immunodeficiency syndrome	6.2e-05	0.000361	CcSEcCtD
Methotrexate—Thrombocytopenia—Lamivudine—acquired immunodeficiency syndrome	6.2e-05	0.00036	CcSEcCtD
Methotrexate—Paraesthesia—Ritonavir—acquired immunodeficiency syndrome	6.19e-05	0.00036	CcSEcCtD
Methotrexate—Urticaria—Efavirenz—acquired immunodeficiency syndrome	6.19e-05	0.00036	CcSEcCtD
Methotrexate—Abdominal pain—Efavirenz—acquired immunodeficiency syndrome	6.16e-05	0.000358	CcSEcCtD
Methotrexate—Body temperature increased—Efavirenz—acquired immunodeficiency syndrome	6.16e-05	0.000358	CcSEcCtD
Methotrexate—Skin disorder—Lamivudine—acquired immunodeficiency syndrome	6.15e-05	0.000358	CcSEcCtD
Methotrexate—Dyspnoea—Ritonavir—acquired immunodeficiency syndrome	6.15e-05	0.000357	CcSEcCtD
Methotrexate—Feeling abnormal—Delavirdine—acquired immunodeficiency syndrome	6.15e-05	0.000357	CcSEcCtD
Methotrexate—Somnolence—Ritonavir—acquired immunodeficiency syndrome	6.13e-05	0.000356	CcSEcCtD
Methotrexate—Hyperhidrosis—Lamivudine—acquired immunodeficiency syndrome	6.12e-05	0.000356	CcSEcCtD
Methotrexate—MTHFR—Selenium Micronutrient Network—TNF—acquired immunodeficiency syndrome	6.12e-05	0.00265	CbGpPWpGaD
Methotrexate—Gastrointestinal pain—Delavirdine—acquired immunodeficiency syndrome	6.1e-05	0.000355	CcSEcCtD
Methotrexate—Nausea—Nelfinavir—acquired immunodeficiency syndrome	6.08e-05	0.000354	CcSEcCtD
Methotrexate—Hypersensitivity—Indinavir—acquired immunodeficiency syndrome	6.08e-05	0.000353	CcSEcCtD
Methotrexate—Dyspepsia—Ritonavir—acquired immunodeficiency syndrome	6.07e-05	0.000353	CcSEcCtD
Methotrexate—Diarrhoea—Zidovudine—acquired immunodeficiency syndrome	6.07e-05	0.000353	CcSEcCtD
Methotrexate—Nausea—Stavudine—acquired immunodeficiency syndrome	6.06e-05	0.000352	CcSEcCtD
Methotrexate—Musculoskeletal discomfort—Saquinavir—acquired immunodeficiency syndrome	6.05e-05	0.000352	CcSEcCtD
Methotrexate—Anorexia—Lamivudine—acquired immunodeficiency syndrome	6.04e-05	0.000351	CcSEcCtD
Methotrexate—Insomnia—Saquinavir—acquired immunodeficiency syndrome	6e-05	0.000349	CcSEcCtD
Methotrexate—Decreased appetite—Ritonavir—acquired immunodeficiency syndrome	6e-05	0.000349	CcSEcCtD
Methotrexate—Nausea—Abacavir—acquired immunodeficiency syndrome	5.97e-05	0.000347	CcSEcCtD
Methotrexate—Paraesthesia—Saquinavir—acquired immunodeficiency syndrome	5.96e-05	0.000347	CcSEcCtD
Methotrexate—Gastrointestinal disorder—Ritonavir—acquired immunodeficiency syndrome	5.96e-05	0.000346	CcSEcCtD
Methotrexate—Fatigue—Ritonavir—acquired immunodeficiency syndrome	5.95e-05	0.000346	CcSEcCtD
Methotrexate—MTHFR—Metabolism—TAT—acquired immunodeficiency syndrome	5.95e-05	0.00258	CbGpPWpGaD
Methotrexate—Urticaria—Delavirdine—acquired immunodeficiency syndrome	5.93e-05	0.000344	CcSEcCtD
Methotrexate—Asthenia—Indinavir—acquired immunodeficiency syndrome	5.92e-05	0.000344	CcSEcCtD
Methotrexate—Dyspnoea—Saquinavir—acquired immunodeficiency syndrome	5.92e-05	0.000344	CcSEcCtD
Methotrexate—Hypotension—Lamivudine—acquired immunodeficiency syndrome	5.92e-05	0.000344	CcSEcCtD
Methotrexate—Somnolence—Saquinavir—acquired immunodeficiency syndrome	5.9e-05	0.000343	CcSEcCtD
Methotrexate—Pain—Ritonavir—acquired immunodeficiency syndrome	5.9e-05	0.000343	CcSEcCtD
Methotrexate—Body temperature increased—Delavirdine—acquired immunodeficiency syndrome	5.9e-05	0.000343	CcSEcCtD
Methotrexate—Abdominal pain—Delavirdine—acquired immunodeficiency syndrome	5.9e-05	0.000343	CcSEcCtD
Methotrexate—Dizziness—Zidovudine—acquired immunodeficiency syndrome	5.87e-05	0.000341	CcSEcCtD
Methotrexate—Dyspepsia—Saquinavir—acquired immunodeficiency syndrome	5.84e-05	0.00034	CcSEcCtD
Methotrexate—Pruritus—Indinavir—acquired immunodeficiency syndrome	5.84e-05	0.000339	CcSEcCtD
Methotrexate—AOX1—Metabolism—TAT—acquired immunodeficiency syndrome	5.81e-05	0.00252	CbGpPWpGaD
Methotrexate—Decreased appetite—Saquinavir—acquired immunodeficiency syndrome	5.77e-05	0.000335	CcSEcCtD
Methotrexate—Musculoskeletal discomfort—Lamivudine—acquired immunodeficiency syndrome	5.77e-05	0.000335	CcSEcCtD
Methotrexate—Hypersensitivity—Efavirenz—acquired immunodeficiency syndrome	5.74e-05	0.000334	CcSEcCtD
Methotrexate—Gastrointestinal disorder—Saquinavir—acquired immunodeficiency syndrome	5.73e-05	0.000333	CcSEcCtD
Methotrexate—Insomnia—Lamivudine—acquired immunodeficiency syndrome	5.73e-05	0.000333	CcSEcCtD
Methotrexate—Fatigue—Saquinavir—acquired immunodeficiency syndrome	5.72e-05	0.000333	CcSEcCtD
Methotrexate—ABCC1—Metabolism of lipids and lipoproteins—AGPS—acquired immunodeficiency syndrome	5.71e-05	0.00248	CbGpPWpGaD
Methotrexate—Paraesthesia—Lamivudine—acquired immunodeficiency syndrome	5.69e-05	0.000331	CcSEcCtD
Methotrexate—Feeling abnormal—Ritonavir—acquired immunodeficiency syndrome	5.68e-05	0.00033	CcSEcCtD
Methotrexate—Pain—Saquinavir—acquired immunodeficiency syndrome	5.68e-05	0.00033	CcSEcCtD
Methotrexate—MTHFR—Disease—APOBEC3G—acquired immunodeficiency syndrome	5.68e-05	0.00246	CbGpPWpGaD
Methotrexate—Dyspnoea—Lamivudine—acquired immunodeficiency syndrome	5.65e-05	0.000328	CcSEcCtD
Methotrexate—Diarrhoea—Indinavir—acquired immunodeficiency syndrome	5.65e-05	0.000328	CcSEcCtD
Methotrexate—Vomiting—Zidovudine—acquired immunodeficiency syndrome	5.64e-05	0.000328	CcSEcCtD
Methotrexate—Gastrointestinal pain—Ritonavir—acquired immunodeficiency syndrome	5.64e-05	0.000328	CcSEcCtD
Methotrexate—Somnolence—Lamivudine—acquired immunodeficiency syndrome	5.63e-05	0.000327	CcSEcCtD
Methotrexate—Rash—Zidovudine—acquired immunodeficiency syndrome	5.59e-05	0.000325	CcSEcCtD
Methotrexate—Asthenia—Efavirenz—acquired immunodeficiency syndrome	5.59e-05	0.000325	CcSEcCtD
Methotrexate—Dermatitis—Zidovudine—acquired immunodeficiency syndrome	5.59e-05	0.000325	CcSEcCtD
Methotrexate—Dyspepsia—Lamivudine—acquired immunodeficiency syndrome	5.58e-05	0.000324	CcSEcCtD
Methotrexate—Headache—Zidovudine—acquired immunodeficiency syndrome	5.56e-05	0.000323	CcSEcCtD
Methotrexate—AOX1—Disease—APOBEC3G—acquired immunodeficiency syndrome	5.54e-05	0.0024	CbGpPWpGaD
Methotrexate—ABCC11—Transmembrane transport of small molecules—ALB—acquired immunodeficiency syndrome	5.54e-05	0.0024	CbGpPWpGaD
Methotrexate—ABCB1—Allograft Rejection—CXCL12—acquired immunodeficiency syndrome	5.53e-05	0.0024	CbGpPWpGaD
Methotrexate—DHFR—Folate Metabolism—IL6—acquired immunodeficiency syndrome	5.53e-05	0.0024	CbGpPWpGaD
Methotrexate—Pruritus—Efavirenz—acquired immunodeficiency syndrome	5.52e-05	0.000321	CcSEcCtD
Methotrexate—Decreased appetite—Lamivudine—acquired immunodeficiency syndrome	5.51e-05	0.00032	CcSEcCtD
Methotrexate—Hypersensitivity—Delavirdine—acquired immunodeficiency syndrome	5.5e-05	0.000319	CcSEcCtD
Methotrexate—Urticaria—Ritonavir—acquired immunodeficiency syndrome	5.48e-05	0.000319	CcSEcCtD
Methotrexate—SLCO1C1—SLC-mediated transmembrane transport—ALB—acquired immunodeficiency syndrome	5.47e-05	0.00237	CbGpPWpGaD
Methotrexate—Feeling abnormal—Saquinavir—acquired immunodeficiency syndrome	5.47e-05	0.000318	CcSEcCtD
Methotrexate—Gastrointestinal disorder—Lamivudine—acquired immunodeficiency syndrome	5.47e-05	0.000318	CcSEcCtD
Methotrexate—Fatigue—Lamivudine—acquired immunodeficiency syndrome	5.46e-05	0.000317	CcSEcCtD
Methotrexate—Dizziness—Indinavir—acquired immunodeficiency syndrome	5.46e-05	0.000317	CcSEcCtD
Methotrexate—Body temperature increased—Ritonavir—acquired immunodeficiency syndrome	5.45e-05	0.000317	CcSEcCtD
Methotrexate—Abdominal pain—Ritonavir—acquired immunodeficiency syndrome	5.45e-05	0.000317	CcSEcCtD
Methotrexate—Gastrointestinal pain—Saquinavir—acquired immunodeficiency syndrome	5.43e-05	0.000316	CcSEcCtD
Methotrexate—SLCO1B1—Metabolism of lipids and lipoproteins—AGPS—acquired immunodeficiency syndrome	5.43e-05	0.00235	CbGpPWpGaD
Methotrexate—Pain—Lamivudine—acquired immunodeficiency syndrome	5.42e-05	0.000315	CcSEcCtD
Methotrexate—FPGS—Disease—CXCR4—acquired immunodeficiency syndrome	5.39e-05	0.00234	CbGpPWpGaD
Methotrexate—ALB—Folate Metabolism—IL4—acquired immunodeficiency syndrome	5.38e-05	0.00233	CbGpPWpGaD
Methotrexate—Asthenia—Delavirdine—acquired immunodeficiency syndrome	5.35e-05	0.000311	CcSEcCtD
Methotrexate—Diarrhoea—Efavirenz—acquired immunodeficiency syndrome	5.33e-05	0.00031	CcSEcCtD
Methotrexate—DHFR—Metabolism—TAT—acquired immunodeficiency syndrome	5.28e-05	0.00229	CbGpPWpGaD
Methotrexate—Pruritus—Delavirdine—acquired immunodeficiency syndrome	5.28e-05	0.000307	CcSEcCtD
Methotrexate—Urticaria—Saquinavir—acquired immunodeficiency syndrome	5.27e-05	0.000307	CcSEcCtD
Methotrexate—Nausea—Zidovudine—acquired immunodeficiency syndrome	5.27e-05	0.000306	CcSEcCtD
Methotrexate—Abdominal pain—Saquinavir—acquired immunodeficiency syndrome	5.25e-05	0.000305	CcSEcCtD
Methotrexate—Body temperature increased—Saquinavir—acquired immunodeficiency syndrome	5.25e-05	0.000305	CcSEcCtD
Methotrexate—Vomiting—Indinavir—acquired immunodeficiency syndrome	5.25e-05	0.000305	CcSEcCtD
Methotrexate—Feeling abnormal—Lamivudine—acquired immunodeficiency syndrome	5.22e-05	0.000303	CcSEcCtD
Methotrexate—Rash—Indinavir—acquired immunodeficiency syndrome	5.2e-05	0.000302	CcSEcCtD
Methotrexate—Dermatitis—Indinavir—acquired immunodeficiency syndrome	5.2e-05	0.000302	CcSEcCtD
Methotrexate—Gastrointestinal pain—Lamivudine—acquired immunodeficiency syndrome	5.18e-05	0.000301	CcSEcCtD
Methotrexate—Headache—Indinavir—acquired immunodeficiency syndrome	5.17e-05	0.0003	CcSEcCtD
Methotrexate—Dizziness—Efavirenz—acquired immunodeficiency syndrome	5.16e-05	0.0003	CcSEcCtD
Methotrexate—Diarrhoea—Delavirdine—acquired immunodeficiency syndrome	5.1e-05	0.000297	CcSEcCtD
Methotrexate—Hypersensitivity—Ritonavir—acquired immunodeficiency syndrome	5.08e-05	0.000295	CcSEcCtD
Methotrexate—MTHFR—Metabolism—AGPS—acquired immunodeficiency syndrome	5.06e-05	0.00219	CbGpPWpGaD
Methotrexate—DHFR—Disease—APOBEC3G—acquired immunodeficiency syndrome	5.04e-05	0.00219	CbGpPWpGaD
Methotrexate—Urticaria—Lamivudine—acquired immunodeficiency syndrome	5.03e-05	0.000292	CcSEcCtD
Methotrexate—Abdominal pain—Lamivudine—acquired immunodeficiency syndrome	5.01e-05	0.000291	CcSEcCtD
Methotrexate—Body temperature increased—Lamivudine—acquired immunodeficiency syndrome	5.01e-05	0.000291	CcSEcCtD
Methotrexate—ABCB1—brain—acquired immunodeficiency syndrome	4.97e-05	0.000684	CbGeAlD
Methotrexate—Vomiting—Efavirenz—acquired immunodeficiency syndrome	4.96e-05	0.000288	CcSEcCtD
Methotrexate—Asthenia—Ritonavir—acquired immunodeficiency syndrome	4.95e-05	0.000288	CcSEcCtD
Methotrexate—MTHFR—Selenium Micronutrient Network—IL6—acquired immunodeficiency syndrome	4.94e-05	0.00214	CbGpPWpGaD
Methotrexate—AOX1—Metabolism—AGPS—acquired immunodeficiency syndrome	4.94e-05	0.00214	CbGpPWpGaD
Methotrexate—Dizziness—Delavirdine—acquired immunodeficiency syndrome	4.93e-05	0.000287	CcSEcCtD
Methotrexate—Rash—Efavirenz—acquired immunodeficiency syndrome	4.92e-05	0.000286	CcSEcCtD
Methotrexate—Dermatitis—Efavirenz—acquired immunodeficiency syndrome	4.91e-05	0.000285	CcSEcCtD
Methotrexate—Nausea—Indinavir—acquired immunodeficiency syndrome	4.9e-05	0.000285	CcSEcCtD
Methotrexate—Hypersensitivity—Saquinavir—acquired immunodeficiency syndrome	4.89e-05	0.000284	CcSEcCtD
Methotrexate—Headache—Efavirenz—acquired immunodeficiency syndrome	4.88e-05	0.000284	CcSEcCtD
Methotrexate—Pruritus—Ritonavir—acquired immunodeficiency syndrome	4.88e-05	0.000284	CcSEcCtD
Methotrexate—MTHFR—Disease—CCNT1—acquired immunodeficiency syndrome	4.83e-05	0.00209	CbGpPWpGaD
Methotrexate—SLC16A1—Metabolism—TAT—acquired immunodeficiency syndrome	4.81e-05	0.00209	CbGpPWpGaD
Methotrexate—ABCB1—lymph node—acquired immunodeficiency syndrome	4.8e-05	0.000661	CbGeAlD
Methotrexate—Asthenia—Saquinavir—acquired immunodeficiency syndrome	4.76e-05	0.000277	CcSEcCtD
Methotrexate—Vomiting—Delavirdine—acquired immunodeficiency syndrome	4.74e-05	0.000276	CcSEcCtD
Methotrexate—Diarrhoea—Ritonavir—acquired immunodeficiency syndrome	4.72e-05	0.000274	CcSEcCtD
Methotrexate—AOX1—Disease—CCNT1—acquired immunodeficiency syndrome	4.71e-05	0.00204	CbGpPWpGaD
Methotrexate—Rash—Delavirdine—acquired immunodeficiency syndrome	4.7e-05	0.000273	CcSEcCtD
Methotrexate—Dermatitis—Delavirdine—acquired immunodeficiency syndrome	4.7e-05	0.000273	CcSEcCtD
Methotrexate—Pruritus—Saquinavir—acquired immunodeficiency syndrome	4.7e-05	0.000273	CcSEcCtD
Methotrexate—Headache—Delavirdine—acquired immunodeficiency syndrome	4.67e-05	0.000272	CcSEcCtD
Methotrexate—Hypersensitivity—Lamivudine—acquired immunodeficiency syndrome	4.67e-05	0.000271	CcSEcCtD
Methotrexate—Nausea—Efavirenz—acquired immunodeficiency syndrome	4.63e-05	0.000269	CcSEcCtD
Methotrexate—TYMS—Metabolism—TAT—acquired immunodeficiency syndrome	4.61e-05	0.002	CbGpPWpGaD
Methotrexate—ABCC4—Platelet activation, signaling and aggregation—CSF2—acquired immunodeficiency syndrome	4.59e-05	0.00199	CbGpPWpGaD
Methotrexate—Dizziness—Ritonavir—acquired immunodeficiency syndrome	4.56e-05	0.000265	CcSEcCtD
Methotrexate—Asthenia—Lamivudine—acquired immunodeficiency syndrome	4.54e-05	0.000264	CcSEcCtD
Methotrexate—Diarrhoea—Saquinavir—acquired immunodeficiency syndrome	4.54e-05	0.000264	CcSEcCtD
Methotrexate—DHFR—Metabolism—AGPS—acquired immunodeficiency syndrome	4.49e-05	0.00195	CbGpPWpGaD
Methotrexate—Pruritus—Lamivudine—acquired immunodeficiency syndrome	4.48e-05	0.00026	CcSEcCtD
Methotrexate—Nausea—Delavirdine—acquired immunodeficiency syndrome	4.43e-05	0.000258	CcSEcCtD
Methotrexate—Dizziness—Saquinavir—acquired immunodeficiency syndrome	4.39e-05	0.000255	CcSEcCtD
Methotrexate—Vomiting—Ritonavir—acquired immunodeficiency syndrome	4.39e-05	0.000255	CcSEcCtD
Methotrexate—Rash—Ritonavir—acquired immunodeficiency syndrome	4.35e-05	0.000253	CcSEcCtD
Methotrexate—SLC19A1—Disease—CCR5—acquired immunodeficiency syndrome	4.35e-05	0.00189	CbGpPWpGaD
Methotrexate—Dermatitis—Ritonavir—acquired immunodeficiency syndrome	4.35e-05	0.000253	CcSEcCtD
Methotrexate—Diarrhoea—Lamivudine—acquired immunodeficiency syndrome	4.33e-05	0.000252	CcSEcCtD
Methotrexate—Headache—Ritonavir—acquired immunodeficiency syndrome	4.32e-05	0.000251	CcSEcCtD
Methotrexate—DHFR—Disease—CCNT1—acquired immunodeficiency syndrome	4.29e-05	0.00186	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism—TAT—acquired immunodeficiency syndrome	4.23e-05	0.00183	CbGpPWpGaD
Methotrexate—Vomiting—Saquinavir—acquired immunodeficiency syndrome	4.22e-05	0.000245	CcSEcCtD
Methotrexate—SLC46A1—Disease—CXCR4—acquired immunodeficiency syndrome	4.2e-05	0.00182	CbGpPWpGaD
Methotrexate—ABCB1—Allograft Rejection—IL10—acquired immunodeficiency syndrome	4.19e-05	0.00182	CbGpPWpGaD
Methotrexate—ABCB1—Allograft Rejection—CD40LG—acquired immunodeficiency syndrome	4.19e-05	0.00182	CbGpPWpGaD
Methotrexate—Dizziness—Lamivudine—acquired immunodeficiency syndrome	4.19e-05	0.000243	CcSEcCtD
Methotrexate—Rash—Saquinavir—acquired immunodeficiency syndrome	4.19e-05	0.000243	CcSEcCtD
Methotrexate—Dermatitis—Saquinavir—acquired immunodeficiency syndrome	4.18e-05	0.000243	CcSEcCtD
Methotrexate—Headache—Saquinavir—acquired immunodeficiency syndrome	4.16e-05	0.000242	CcSEcCtD
Methotrexate—Nausea—Ritonavir—acquired immunodeficiency syndrome	4.1e-05	0.000238	CcSEcCtD
Methotrexate—SLC16A1—Metabolism—AGPS—acquired immunodeficiency syndrome	4.09e-05	0.00177	CbGpPWpGaD
Methotrexate—ABCB1—Allograft Rejection—IL4—acquired immunodeficiency syndrome	4.08e-05	0.00177	CbGpPWpGaD
Methotrexate—SLC16A1—Hemostasis—IFNA1—acquired immunodeficiency syndrome	4.06e-05	0.00176	CbGpPWpGaD
Methotrexate—Vomiting—Lamivudine—acquired immunodeficiency syndrome	4.03e-05	0.000234	CcSEcCtD
Methotrexate—ALB—Vitamin B12 Metabolism—IFNG—acquired immunodeficiency syndrome	4e-05	0.00173	CbGpPWpGaD
Methotrexate—Rash—Lamivudine—acquired immunodeficiency syndrome	3.99e-05	0.000232	CcSEcCtD
Methotrexate—ABCB1—Allograft Rejection—HLA-B—acquired immunodeficiency syndrome	3.99e-05	0.00173	CbGpPWpGaD
Methotrexate—Dermatitis—Lamivudine—acquired immunodeficiency syndrome	3.99e-05	0.000232	CcSEcCtD
Methotrexate—Headache—Lamivudine—acquired immunodeficiency syndrome	3.97e-05	0.000231	CcSEcCtD
Methotrexate—Nausea—Saquinavir—acquired immunodeficiency syndrome	3.94e-05	0.000229	CcSEcCtD
Methotrexate—TYMS—Metabolism—AGPS—acquired immunodeficiency syndrome	3.92e-05	0.0017	CbGpPWpGaD
Methotrexate—PGD—Disease—CXCR4—acquired immunodeficiency syndrome	3.84e-05	0.00167	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism—TAT—acquired immunodeficiency syndrome	3.82e-05	0.00165	CbGpPWpGaD
Methotrexate—Nausea—Lamivudine—acquired immunodeficiency syndrome	3.76e-05	0.000219	CcSEcCtD
Methotrexate—FPGS—Disease—CCR5—acquired immunodeficiency syndrome	3.7e-05	0.0016	CbGpPWpGaD
Methotrexate—SLC46A1—Transmembrane transport of small molecules—ALB—acquired immunodeficiency syndrome	3.67e-05	0.00159	CbGpPWpGaD
Methotrexate—ABCC10—Transmembrane transport of small molecules—ALB—acquired immunodeficiency syndrome	3.67e-05	0.00159	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism—AGPS—acquired immunodeficiency syndrome	3.6e-05	0.00156	CbGpPWpGaD
Methotrexate—SLC22A11—SLC-mediated transmembrane transport—ALB—acquired immunodeficiency syndrome	3.6e-05	0.00156	CbGpPWpGaD
Methotrexate—SLC16A1—SLC-mediated transmembrane transport—ALB—acquired immunodeficiency syndrome	3.53e-05	0.00153	CbGpPWpGaD
Methotrexate—SLCO3A1—Transmembrane transport of small molecules—ALB—acquired immunodeficiency syndrome	3.48e-05	0.00151	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—TAT—acquired immunodeficiency syndrome	3.32e-05	0.00144	CbGpPWpGaD
Methotrexate—SLCO4C1—Transmembrane transport of small molecules—ALB—acquired immunodeficiency syndrome	3.32e-05	0.00144	CbGpPWpGaD
Methotrexate—SLC22A7—SLC-mediated transmembrane transport—ALB—acquired immunodeficiency syndrome	3.26e-05	0.00141	CbGpPWpGaD
Methotrexate—ALB—Folate Metabolism—IFNG—acquired immunodeficiency syndrome	3.25e-05	0.00141	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism—AGPS—acquired immunodeficiency syndrome	3.24e-05	0.00141	CbGpPWpGaD
Methotrexate—SLC16A1—Hemostasis—CSF2—acquired immunodeficiency syndrome	3.18e-05	0.00138	CbGpPWpGaD
Methotrexate—ALB—Metabolism of lipids and lipoproteins—AGPS—acquired immunodeficiency syndrome	3.1e-05	0.00134	CbGpPWpGaD
Methotrexate—SLCO1B3—SLC-mediated transmembrane transport—ALB—acquired immunodeficiency syndrome	3.1e-05	0.00134	CbGpPWpGaD
Methotrexate—ABCC4—Hemostasis—IFNA1—acquired immunodeficiency syndrome	3.03e-05	0.00131	CbGpPWpGaD
Methotrexate—ABCC4—Platelet activation, signaling and aggregation—ALB—acquired immunodeficiency syndrome	2.99e-05	0.0013	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—TAT—acquired immunodeficiency syndrome	2.99e-05	0.0013	CbGpPWpGaD
Methotrexate—ALB—Folate Metabolism—IL2—acquired immunodeficiency syndrome	2.89e-05	0.00125	CbGpPWpGaD
Methotrexate—SLC46A1—Disease—CCR5—acquired immunodeficiency syndrome	2.88e-05	0.00125	CbGpPWpGaD
Methotrexate—ABCC1—Disease—APOBEC3G—acquired immunodeficiency syndrome	2.85e-05	0.00124	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—TAT—acquired immunodeficiency syndrome	2.84e-05	0.00123	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—AGPS—acquired immunodeficiency syndrome	2.83e-05	0.00123	CbGpPWpGaD
Methotrexate—SLCO1C1—Transmembrane transport of small molecules—ALB—acquired immunodeficiency syndrome	2.78e-05	0.00121	CbGpPWpGaD
Methotrexate—SLC22A8—SLC-mediated transmembrane transport—ALB—acquired immunodeficiency syndrome	2.74e-05	0.00119	CbGpPWpGaD
Methotrexate—SLC19A1—Disease—CD4—acquired immunodeficiency syndrome	2.73e-05	0.00118	CbGpPWpGaD
Methotrexate—PGD—Disease—CCR5—acquired immunodeficiency syndrome	2.63e-05	0.00114	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—TAT—acquired immunodeficiency syndrome	2.63e-05	0.00114	CbGpPWpGaD
Methotrexate—SLC19A1—Metabolism—ALB—acquired immunodeficiency syndrome	2.59e-05	0.00112	CbGpPWpGaD
Methotrexate—ALB—Vitamin B12 Metabolism—TNF—acquired immunodeficiency syndrome	2.59e-05	0.00112	CbGpPWpGaD
Methotrexate—ALB—Selenium Micronutrient Network—IFNG—acquired immunodeficiency syndrome	2.58e-05	0.00112	CbGpPWpGaD
Methotrexate—TYMS—Integrated Pancreatic Cancer Pathway—TNF—acquired immunodeficiency syndrome	2.55e-05	0.00111	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—AGPS—acquired immunodeficiency syndrome	2.54e-05	0.0011	CbGpPWpGaD
Methotrexate—MTHFR—Disease—CXCR4—acquired immunodeficiency syndrome	2.54e-05	0.0011	CbGpPWpGaD
Methotrexate—AOX1—Disease—CXCR4—acquired immunodeficiency syndrome	2.48e-05	0.00107	CbGpPWpGaD
Methotrexate—ABCB1—Allograft Rejection—IFNG—acquired immunodeficiency syndrome	2.47e-05	0.00107	CbGpPWpGaD
Methotrexate—SLCO1A2—SLC-mediated transmembrane transport—ALB—acquired immunodeficiency syndrome	2.43e-05	0.00106	CbGpPWpGaD
Methotrexate—ABCC4—Platelet activation, signaling and aggregation—IL2—acquired immunodeficiency syndrome	2.43e-05	0.00105	CbGpPWpGaD
Methotrexate—ABCC1—Disease—CCNT1—acquired immunodeficiency syndrome	2.43e-05	0.00105	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—AGPS—acquired immunodeficiency syndrome	2.42e-05	0.00105	CbGpPWpGaD
Methotrexate—ABCC4—Hemostasis—CSF2—acquired immunodeficiency syndrome	2.37e-05	0.00103	CbGpPWpGaD
Methotrexate—FPGS—Disease—CD4—acquired immunodeficiency syndrome	2.32e-05	0.00101	CbGpPWpGaD
Methotrexate—SLC22A6—SLC-mediated transmembrane transport—ALB—acquired immunodeficiency syndrome	2.29e-05	0.000992	CbGpPWpGaD
Methotrexate—DHFR—Disease—CXCR4—acquired immunodeficiency syndrome	2.25e-05	0.000977	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—AGPS—acquired immunodeficiency syndrome	2.24e-05	0.00097	CbGpPWpGaD
Methotrexate—ATIC—Metabolism—ALB—acquired immunodeficiency syndrome	2.21e-05	0.000956	CbGpPWpGaD
Methotrexate—FPGS—Metabolism—ALB—acquired immunodeficiency syndrome	2.21e-05	0.000956	CbGpPWpGaD
Methotrexate—ABCB1—Allograft Rejection—IL2—acquired immunodeficiency syndrome	2.19e-05	0.000951	CbGpPWpGaD
Methotrexate—ALB—Folate Metabolism—TNF—acquired immunodeficiency syndrome	2.1e-05	0.000912	CbGpPWpGaD
Methotrexate—ALB—Vitamin B12 Metabolism—IL6—acquired immunodeficiency syndrome	2.09e-05	0.000905	CbGpPWpGaD
Methotrexate—SLCO1B1—SLC-mediated transmembrane transport—ALB—acquired immunodeficiency syndrome	2.08e-05	0.000903	CbGpPWpGaD
Methotrexate—ALB—Platelet activation, signaling and aggregation—CSF2—acquired immunodeficiency syndrome	2.08e-05	0.000901	CbGpPWpGaD
Methotrexate—SLC16A1—Hemostasis—ALB—acquired immunodeficiency syndrome	2.07e-05	0.000898	CbGpPWpGaD
Methotrexate—TYMS—Circadian rythm related genes—IL6—acquired immunodeficiency syndrome	1.98e-05	0.000858	CbGpPWpGaD
Methotrexate—SLC22A11—Transmembrane transport of small molecules—ALB—acquired immunodeficiency syndrome	1.83e-05	0.000792	CbGpPWpGaD
Methotrexate—SLC46A1—Disease—CD4—acquired immunodeficiency syndrome	1.81e-05	0.000784	CbGpPWpGaD
Methotrexate—SLC16A1—Transmembrane transport of small molecules—ALB—acquired immunodeficiency syndrome	1.79e-05	0.000777	CbGpPWpGaD
Methotrexate—MTHFR—Disease—CCR5—acquired immunodeficiency syndrome	1.74e-05	0.000754	CbGpPWpGaD
Methotrexate—SLC46A1—Metabolism—ALB—acquired immunodeficiency syndrome	1.72e-05	0.000745	CbGpPWpGaD
Methotrexate—ALB—Folate Metabolism—IL6—acquired immunodeficiency syndrome	1.7e-05	0.000736	CbGpPWpGaD
Methotrexate—AOX1—Disease—CCR5—acquired immunodeficiency syndrome	1.7e-05	0.000736	CbGpPWpGaD
Methotrexate—SLC16A1—Hemostasis—IL2—acquired immunodeficiency syndrome	1.68e-05	0.000728	CbGpPWpGaD
Methotrexate—ALB—Selenium Micronutrient Network—TNF—acquired immunodeficiency syndrome	1.67e-05	0.000725	CbGpPWpGaD
Methotrexate—SLC22A7—Transmembrane transport of small molecules—ALB—acquired immunodeficiency syndrome	1.66e-05	0.000719	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism of lipids and lipoproteins—ALB—acquired immunodeficiency syndrome	1.66e-05	0.000718	CbGpPWpGaD
Methotrexate—PGD—Disease—CD4—acquired immunodeficiency syndrome	1.65e-05	0.000717	CbGpPWpGaD
Methotrexate—ALB—Metabolism—TAT—acquired immunodeficiency syndrome	1.62e-05	0.000704	CbGpPWpGaD
Methotrexate—ABCB1—Allograft Rejection—TNF—acquired immunodeficiency syndrome	1.6e-05	0.000692	CbGpPWpGaD
Methotrexate—SLCO1B3—Transmembrane transport of small molecules—ALB—acquired immunodeficiency syndrome	1.57e-05	0.000683	CbGpPWpGaD
Methotrexate—PGD—Metabolism—ALB—acquired immunodeficiency syndrome	1.57e-05	0.000682	CbGpPWpGaD
Methotrexate—DHFR—Disease—CCR5—acquired immunodeficiency syndrome	1.54e-05	0.00067	CbGpPWpGaD
Methotrexate—ABCC4—Hemostasis—ALB—acquired immunodeficiency syndrome	1.54e-05	0.000669	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism of lipids and lipoproteins—ALB—acquired immunodeficiency syndrome	1.49e-05	0.000648	CbGpPWpGaD
Methotrexate—SLC19A1—Disease—IL6—acquired immunodeficiency syndrome	1.48e-05	0.00064	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—TAT—acquired immunodeficiency syndrome	1.42e-05	0.000617	CbGpPWpGaD
Methotrexate—ABCC3—Transmembrane transport of small molecules—ALB—acquired immunodeficiency syndrome	1.42e-05	0.000616	CbGpPWpGaD
Methotrexate—SLC22A8—Transmembrane transport of small molecules—ALB—acquired immunodeficiency syndrome	1.39e-05	0.000604	CbGpPWpGaD
Methotrexate—ALB—Metabolism—AGPS—acquired immunodeficiency syndrome	1.38e-05	0.000599	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—IFNA1—acquired immunodeficiency syndrome	1.37e-05	0.000594	CbGpPWpGaD
Methotrexate—ALB—Selenium Micronutrient Network—IL6—acquired immunodeficiency syndrome	1.35e-05	0.000585	CbGpPWpGaD
Methotrexate—ABCC4—Transmembrane transport of small molecules—ALB—acquired immunodeficiency syndrome	1.34e-05	0.000579	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism of lipids and lipoproteins—ALB—acquired immunodeficiency syndrome	1.3e-05	0.000564	CbGpPWpGaD
Methotrexate—ABCC1—Disease—CXCR4—acquired immunodeficiency syndrome	1.27e-05	0.000553	CbGpPWpGaD
Methotrexate—FPGS—Disease—IL6—acquired immunodeficiency syndrome	1.26e-05	0.000544	CbGpPWpGaD
Methotrexate—ABCC4—Hemostasis—IL2—acquired immunodeficiency syndrome	1.25e-05	0.000543	CbGpPWpGaD
Methotrexate—SLCO1A2—Transmembrane transport of small molecules—ALB—acquired immunodeficiency syndrome	1.24e-05	0.000537	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—AGPS—acquired immunodeficiency syndrome	1.21e-05	0.000525	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism of lipids and lipoproteins—ALB—acquired immunodeficiency syndrome	1.17e-05	0.000508	CbGpPWpGaD
Methotrexate—SLC22A6—Transmembrane transport of small molecules—ALB—acquired immunodeficiency syndrome	1.16e-05	0.000504	CbGpPWpGaD
Methotrexate—ABCC2—Transmembrane transport of small molecules—ALB—acquired immunodeficiency syndrome	1.13e-05	0.000488	CbGpPWpGaD
Methotrexate—ABCC1—Transmembrane transport of small molecules—ALB—acquired immunodeficiency syndrome	1.11e-05	0.000483	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism of lipids and lipoproteins—ALB—acquired immunodeficiency syndrome	1.11e-05	0.000483	CbGpPWpGaD
Methotrexate—ALB—Platelet activation, signaling and aggregation—IL2—acquired immunodeficiency syndrome	1.1e-05	0.000476	CbGpPWpGaD
Methotrexate—MTHFR—Disease—CD4—acquired immunodeficiency syndrome	1.09e-05	0.000473	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—CSF2—acquired immunodeficiency syndrome	1.07e-05	0.000465	CbGpPWpGaD
Methotrexate—AOX1—Disease—CD4—acquired immunodeficiency syndrome	1.07e-05	0.000462	CbGpPWpGaD
Methotrexate—SLCO1B1—Transmembrane transport of small molecules—ALB—acquired immunodeficiency syndrome	1.06e-05	0.000459	CbGpPWpGaD
Methotrexate—MTHFR—Metabolism—ALB—acquired immunodeficiency syndrome	1.04e-05	0.00045	CbGpPWpGaD
Methotrexate—AOX1—Metabolism—ALB—acquired immunodeficiency syndrome	1.01e-05	0.000439	CbGpPWpGaD
Methotrexate—ABCG2—Transmembrane transport of small molecules—ALB—acquired immunodeficiency syndrome	9.8e-06	0.000425	CbGpPWpGaD
Methotrexate—SLC46A1—Disease—IL6—acquired immunodeficiency syndrome	9.78e-06	0.000424	CbGpPWpGaD
Methotrexate—DHFR—Disease—CD4—acquired immunodeficiency syndrome	9.7e-06	0.00042	CbGpPWpGaD
Methotrexate—DHFR—Metabolism—ALB—acquired immunodeficiency syndrome	9.21e-06	0.0004	CbGpPWpGaD
Methotrexate—PGD—Disease—IL6—acquired immunodeficiency syndrome	8.94e-06	0.000388	CbGpPWpGaD
Methotrexate—ABCC1—Disease—CCR5—acquired immunodeficiency syndrome	8.74e-06	0.000379	CbGpPWpGaD
Methotrexate—SLC16A1—Metabolism—ALB—acquired immunodeficiency syndrome	8.39e-06	0.000364	CbGpPWpGaD
Methotrexate—TYMS—Metabolism—ALB—acquired immunodeficiency syndrome	8.04e-06	0.000349	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—acquired immunodeficiency syndrome	7.88e-06	0.000342	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism—ALB—acquired immunodeficiency syndrome	7.38e-06	0.00032	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism—ALB—acquired immunodeficiency syndrome	6.65e-06	0.000289	CbGpPWpGaD
Methotrexate—MTHFR—Disease—IL6—acquired immunodeficiency syndrome	5.9e-06	0.000256	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—ALB—acquired immunodeficiency syndrome	5.79e-06	0.000251	CbGpPWpGaD
Methotrexate—AOX1—Disease—IL6—acquired immunodeficiency syndrome	5.76e-06	0.00025	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—IL2—acquired immunodeficiency syndrome	5.66e-06	0.000246	CbGpPWpGaD
Methotrexate—ABCC1—Disease—CD4—acquired immunodeficiency syndrome	5.49e-06	0.000238	CbGpPWpGaD
Methotrexate—ABCB1—Transmembrane transport of small molecules—ALB—acquired immunodeficiency syndrome	5.3e-06	0.00023	CbGpPWpGaD
Methotrexate—DHFR—Disease—IL6—acquired immunodeficiency syndrome	5.24e-06	0.000227	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—ALB—acquired immunodeficiency syndrome	5.21e-06	0.000226	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—ALB—acquired immunodeficiency syndrome	4.96e-06	0.000215	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—ALB—acquired immunodeficiency syndrome	4.59e-06	0.000199	CbGpPWpGaD
Methotrexate—ABCC1—Disease—IL6—acquired immunodeficiency syndrome	2.97e-06	0.000129	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—ALB—acquired immunodeficiency syndrome	2.48e-06	0.000108	CbGpPWpGaD
